Roger Jeffs
CIK 1231615 · Chief Executive Officer · last filed 2026-10-13
Roger Jeffs is a Chief Executive Officer who has filed 376 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing, for LQDA, was dated Oct 13, 2026. Across all open-market trades the lifetime net is −$194.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $83.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
UTHR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LQDA | Chief Executive Officer | 1,190,854 | $48.01 | $57.17M | -$33.38M | 40 | 2026-10-13 |
| AXSM | Director | 105,565 | $133.06 | $14.05M | -$15.63M | 31 | 2026-06-11 |
| ALBIREO PHARMA, INC. (ALBO) Delisted | Director | — | $44.15 | — | $0 | 6 | 2021-06-28 |
| Dova Pharmaceuticals Inc. (DOVA) Delisted | Director | 0 | — | — | $701.9K | 7 | 2019-11-12 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | Director | 9,908 | $0.18 | $1.8K | $100.5K | 3 | 2018-09-07 |
| UTHR | President & Co-CEO | 20,486 | $584.36 | $11.97M | -$146.64M | 268 | 2016-03-15 |
Recent Filings
376 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-13 | LQDA | Mixed | −4,578 | -$932.5K | EDGAR |
| 2026-07-14 | LQDA | Mixed | −7,082 | -$2.52M | EDGAR |
| 2026-06-11 | AXSM | Notice (144) | −286 | -$71.2K | EDGAR |
| 2026-06-11 | AXSM | Sell (S) | −572 | -$141.7K | EDGAR |
| 2026-06-10 | AXSM | Notice (144) | −286 | -$70.4K | EDGAR |
| 2026-06-10 | AXSM | Exer (M) | +1,429 | $0 | EDGAR |
| 2026-06-09 | AXSM | Grant (A) | — | $0 | EDGAR |
| 2026-05-28 | LQDA | Sell (S) | −6,428 | -$399.7K | EDGAR |
| 2026-05-26 | LQDA | Sell (S) | −75,000 | -$4.58M | EDGAR |
| 2026-05-20 | LQDA | Notice (144) | −106,428 | -$6.38M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.